• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成人 T 细胞淋巴母细胞淋巴瘤中 microRNA 特征的预后和预测价值。

Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.

机构信息

State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Department of Pharmacology, College of Pharmacy, Jinan University, Guangzhou, China.

出版信息

Leukemia. 2019 Oct;33(10):2454-2465. doi: 10.1038/s41375-019-0466-0. Epub 2019 Apr 5.

DOI:10.1038/s41375-019-0466-0
PMID:30953029
Abstract

New prognostic factors are needed to establish indications for haematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) for T-cell lymphoblastic lymphoma (T-LBL) patients. We used microarray to compare T-LBL tissue samples (n = 75) and fetal thymus tissues (n = 20), and identified 35 differentially expressed miRNAs. Using 107 subjects as the training group, we developed a five-miRNA-based classifier to predict patient survival with LASSO Cox regression: lower risk was associated with better prognosis (disease-free survival (DFS): hazard ratio (HR) 4.548, 95% CI 2.433-8.499, p < 0.001; overall survival (OS): HR 5.030, 95% CI 2.407-10.513, p < 0.001). This classifier displayed good performance in the internal testing set (n = 106) and the independent external set (n = 304). High risk was associated with more favorable response to HSCT (DFS: HR 1.675, 95% CI 1.127-2.488, p = 0.011; OS: HR 1.602, 95% CI 1.055-2.433, p = 0.027). When combined with ECOG-PS and/or NOTCH1/FBXW7 status, this classifier had even better prognostic performance in patients receiving HSCT (DFS: HR 2.088, 95% CI 1.290-3.379, p = 0.003; OS: HR 1.996, 95% CI 1.203-3.311, p = 0.007). The five-miRNA classifier may be a useful prognostic biomarker for T-LBL adults, and could identify subjects who could benefit from HSCT.

摘要

需要新的预后因素来确定 T 细胞淋巴母细胞淋巴瘤(T-LBL)患者首次完全缓解(CR1)时进行造血干细胞移植(HSCT)的适应证。我们使用微阵列比较了 T-LBL 组织样本(n=75)和胎儿胸腺组织(n=20),并鉴定了 35 个差异表达的 miRNA。使用 107 名患者作为训练组,我们通过 LASSO Cox 回归开发了一个基于 5 个 miRNA 的分类器来预测患者的生存情况:低风险与更好的预后相关(无病生存(DFS):风险比(HR)4.548,95%CI 2.433-8.499,p<0.001;总生存(OS):HR 5.030,95%CI 2.407-10.513,p<0.001)。该分类器在内部测试集(n=106)和独立外部集(n=304)中表现出良好的性能。高风险与 HSCT 更有利的反应相关(DFS:HR 1.675,95%CI 1.127-2.488,p=0.011;OS:HR 1.602,95%CI 1.055-2.433,p=0.027)。当与 ECOG-PS 和/或 NOTCH1/FBXW7 状态结合使用时,该分类器在接受 HSCT 的患者中具有更好的预后性能(DFS:HR 2.088,95%CI 1.290-3.379,p=0.003;OS:HR 1.996,95%CI 1.203-3.311,p=0.007)。五 miRNA 分类器可能是 T-LBL 成人的一种有用的预后生物标志物,可识别可能从 HSCT 中受益的患者。

相似文献

1
Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.成人 T 细胞淋巴母细胞淋巴瘤中 microRNA 特征的预后和预测价值。
Leukemia. 2019 Oct;33(10):2454-2465. doi: 10.1038/s41375-019-0466-0. Epub 2019 Apr 5.
2
Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.miRNA 标志物在 II 期结肠癌中的预后和预测价值:miRNA 表达分析
Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13.
3
A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study.基于基因表达的标志可预测成人 T 细胞淋巴母细胞淋巴瘤的生存情况:一项多中心研究。
Leukemia. 2020 Sep;34(9):2392-2404. doi: 10.1038/s41375-020-0757-5. Epub 2020 Feb 20.
4
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.根据强化治疗后流式细胞术评估的早期细胞形态学反应和微小残留病对青少年和成人高危费城染色体阴性急性淋巴细胞白血病的治疗:PETHEMA ALL-AR-03 试验的最终结果。
J Clin Oncol. 2014 May 20;32(15):1595-604. doi: 10.1200/JCO.2013.52.2425. Epub 2014 Apr 21.
5
Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.中国单中心成人急性淋巴细胞白血病自体造血干细胞移植后的结局及移植前微小残留病的意义分析
Chin Med J (Engl). 2015 Aug 5;128(15):2065-71. doi: 10.4103/0366-6999.161365.
6
A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma.CpG 甲基化分类器预测 T 细胞淋巴母细胞淋巴瘤成人患者的复发。
Clin Cancer Res. 2020 Jul 15;26(14):3760-3770. doi: 10.1158/1078-0432.CCR-19-4207. Epub 2020 Mar 31.
7
Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.异基因 BMT 前后持续的微小残留病可预测儿童急性淋巴细胞白血病的复发。
Br J Haematol. 2015 Feb;168(3):395-404. doi: 10.1111/bjh.13142. Epub 2014 Oct 14.
8
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.异基因造血干细胞移植与酪氨酸激酶抑制剂联合化疗治疗费城染色体阳性急性淋巴细胞白血病。
Biol Blood Marrow Transplant. 2018 Apr;24(4):741-750. doi: 10.1016/j.bbmt.2017.12.777. Epub 2017 Dec 13.
9
Lymphoblastic lymphoma.淋巴母细胞淋巴瘤。
Crit Rev Oncol Hematol. 2011 Sep;79(3):330-43. doi: 10.1016/j.critrevonc.2010.12.003. Epub 2011 Jan 26.
10
[Comparative analysis between autologous and allogeneic hematopoietic stem cell transplantation in 114 adult patients with acute lymphoblastic leukemia in long-term follow-up].114例成人急性淋巴细胞白血病患者自体与异基因造血干细胞移植的长期随访比较分析
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1325-9.

引用本文的文献

1
A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a multicenter cohort study.基于长链非编码RNA的血清标志物预测ado曲妥珠单抗(T-DM1)治疗HER2+转移性乳腺癌患者的获益:一项多中心队列研究
Cell Death Discov. 2025 Sep 9;11(1):421. doi: 10.1038/s41420-025-02701-8.
2
The AC010247.2/miR-125b-5p axis triggers the malignant progression of acute myelocytic leukemia by IL-6R.AC010247.2/miR-125b-5p轴通过白细胞介素-6受体触发急性髓细胞白血病的恶性进展。
Heliyon. 2024 Sep 10;10(18):e37715. doi: 10.1016/j.heliyon.2024.e37715. eCollection 2024 Sep 30.
3
MicroRNAs utilization as effective factors on hematopoietic stem cell transplantation, its outcomes and prognosis; a comprehensive systematic review.
微小 RNA 作为影响造血干细胞移植效果及预后的有效因素的利用:一项全面的系统综述。
BMC Cancer. 2024 Jul 24;24(1):890. doi: 10.1186/s12885-024-12640-9.
4
Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL.Notch3 调控的 microRNAs 损害了 CXCR4 依赖的胸腺细胞成熟,从而允许 T-ALL 的维持和进展。
Oncogene. 2024 Aug;43(34):2535-2547. doi: 10.1038/s41388-024-03079-0. Epub 2024 Jun 21.
5
Targeting P21-activated kinase suppresses proliferation and enhances chemosensitivity in T-cell lymphoblastic lymphoma.靶向p21活化激酶可抑制T细胞淋巴母细胞淋巴瘤的增殖并增强其化疗敏感性。
Blood Sci. 2023 Jul 18;5(4):249-257. doi: 10.1097/BS9.0000000000000169. eCollection 2023 Oct.
6
The β-catenin-LINC00183-miR-371b-5p-Smad2/LEF1 axis promotes adult T-cell lymphoblastic lymphoma progression and chemoresistance.β-连环蛋白-LINC00183- miR-371b-5p-Smad2/LEF1 轴促进成人 T 细胞性淋巴母细胞淋巴瘤的进展和化疗耐药性。
J Exp Clin Cancer Res. 2023 Apr 28;42(1):105. doi: 10.1186/s13046-023-02670-9.
7
Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review.通过多组学方法提高液体活检的临床潜力:一项系统综述。
Front Genet. 2023 Apr 3;14:1152470. doi: 10.3389/fgene.2023.1152470. eCollection 2023.
8
Human circulating small non-coding RNA signature as a non-invasive biomarker in clinical diagnosis of acute myeloid leukaemia.人循环小非编码 RNA 特征作为急性髓细胞白血病临床诊断的无创生物标志物。
Theranostics. 2023 Feb 13;13(4):1289-1301. doi: 10.7150/thno.80054. eCollection 2023.
9
Comprehensive view on genetic features, therapeutic modalities and prognostic models in adult T-cell lymphoblastic lymphoma.成人T细胞淋巴母细胞淋巴瘤的遗传特征、治疗方式及预后模型综述
Blood Sci. 2022 Jul 6;4(3):155-160. doi: 10.1097/BS9.0000000000000114. eCollection 2022 Jul.
10
Lymphoblastic Lymphoma: a Concise Review.淋巴母细胞淋巴瘤:简要综述。
Curr Oncol Rep. 2022 Jan;24(1):1-12. doi: 10.1007/s11912-021-01168-x. Epub 2022 Jan 20.